Clinical Trial Update: NAsal Polyps: Inflammatory & Molecular Phenotyping of Responders to Benralizumab [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating inflammatory and molecular phenotyping of responders to benralizumab in nasal polyps has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinosinusitis with Nasal Polyps

Drugs mentioned

• FASENRA (BENRALIZUMAB)

Snippet

Sponsor: Humanitas Clinical and Research Center | Conditions: Nasal Polyps | Phase 3 | Status: COMPLETED